Ipsen and Inspiration Biopharmaceuticals to create haemophilia portfolio

Published: 21-Jan-2010
Finance

French pharmaceutical firm Ipsen and US haemophilia specialist Inspiration Biopharmaceuticals are to develop a portfolio of haemophilia drugs that could yield sales of US$1bn over the next 10 years.


French pharmaceutical firm Ipsen and US haemophilia specialist Inspiration Biopharmaceuticals are to develop a portfolio of haemophilia drugs that could yield sales of US$1bn over the next 10 years.

Ipsen will first take a 20% stake in Inspiration for US$85m and could increase this to 47% for milestone payments of up to US$174m based on the successful development of leading product candidates IB1001 and OBI-1, which are scheduled to begin Phase III clinical testing this year.

Upon certain triggering events, Ipsen could acquire full control of Inspiration.

The deal is expected to close in the first quarter of 2010.

Under the terms of the agreement, Ipsen will provide up to US$259m of funding to Inspiration for further development of IB1001 and OBI-1.

John Taylor, co-founder of Inspiration, said the addition of OBI-1 would make the company a worldwide leader in haemophilia "providing a broad range of treatment options for individuals suffering from bleeding disorders".

  • Companies:
  • Ipsen
See more

You may also like

Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

Read more
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology

Trending Articles

  1. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  2. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  3. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
  4. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Finance

Ipsen and Exelixis enter into exclusive licensing agreement for cancer therapy cabozantinib

The agreement includes up to US$545m of potential commercial milestones
Finance

Ipsen acquires OctreoPharm Sciences for €50m

Strengthening its presence in the oncology field
Research & Development

Ipsen enters into option agreement to buy Canbex Therapeutics

Pays €6m upfront to acquire company at completion of Phase IIa study of treatment for spasticity in people with MS
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Subscribe now